Recombinant modified Bacillus anthracis protective antigen for use in vaccines

US7261900B2 · kind B2 · utility

Assignee

• The United States of America as Represented by the Secretary of the Department of Health and Human Services · US

Inventors

• Stephen H. Leppla · Bethesda, US
• Mary Jo Rosovitz · Germantown, US
• John B. Robbins · New York, US
• Rachel Schneerson · Bethesda, US

Key dates

• Filing date: Aug 8, 2003
• Grant date: Aug 28, 2007
• Expiry date: May 7, 2024

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2039/53
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to improved methods of producing and recovering sporulation-deficient B. anthracis mutant stains, and for producing and recovering recombinant B. anthracis protective antigen (PA), especially modified PA which is protease resistant, and to methods of using of these PAs or nucleic acids encoding these PAs for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, B. anthracis bacterial infections and which are useful to prevent and/or treat illnesses caused by B. anthracis, such as inhalation anthrax, cutaneous anthrax and gastrointestinal anthrax.